CAR-T Cell Therapy Deal Benchmarks

Median Upfront

$104M

Range: $48M - $159M

Total Deal Value

$1.0B

Range: $559M - $1.5B

Royalty Rate

8.9% - 15.7%

Tiered up to 19.7%

Dev Milestones

$365M

Range: $204M - $526M

Model Your Deal

Market Analysis

CAR-T cell therapy continues to drive some of the most substantial licensing transactions in hematologic oncology. Phase 1 CAR-T deals carry a median total deal value of $1.0B, reflecting the transformative clinical potential and high manufacturing complexity of engineered cell therapies. Upfront payments range from $48M to $159M.

Given the early clinical stage, CAR-T deal structures are heavily milestone-weighted. Development milestones average $365M, reflecting the significant clinical de-risking required around cytokine release syndrome management, persistence, and manufacturing scalability. Commercial milestones of $228M reward the path to blockbuster status.

Royalty structures for CAR-T deals start at 8.9%-15.7% base rates, with escalation tiers reaching 19.7%. The manufacturing economics of autologous versus allogeneic approaches significantly influence deal terms, with allogeneic platforms often commanding higher total deal values due to broader commercial potential.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What are typical deal terms for a Phase 1 CAR-T licensing agreement?

Phase 1 CAR-T deals typically feature $104M median upfront payments with total deal values reaching $1.0B. The milestone-heavy structure (90% milestones) reflects the early clinical stage and high de-risking potential.

How do hematologic CAR-T deals differ from solid tumor CAR-T deals?

Hematologic CAR-T deals generally command higher valuations than solid tumor CAR-T due to established clinical proof of concept and approved products in heme malignancies. Solid tumor CAR-T remains earlier stage with greater technical risk around tumor microenvironment penetration and T-cell exhaustion.

What royalty rates are common in CAR-T licensing deals?

CAR-T base royalty rates range from 8.9% to 15.7%, with tiered escalation up to 19.7%. The rates account for the unique manufacturing cost structure and pricing dynamics of cell therapies.

What drives upfront payment size in CAR-T deals?

Key factors influencing CAR-T upfront payments include target antigen validation, manufacturing platform maturity (autologous vs. allogeneic), clinical data quality, and competitive landscape density. First-in-class targets or novel constructs with safety advantages command the highest premiums.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

CAR-T Cell Therapy Deal Benchmarks

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Gene Therapy Deals

Multiple Myeloma Deals

Preclinical Deal Benchmarks

Oncology Deal Overview 2026

Ready to Calculate Your Deal Terms?